Masafumi Yasunaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masafumi Yasunaga has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Hideaki Yahata
Department of Gynecology and Obstetrics, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
4 shared publications - Kiyoko Kato
Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
4 shared publications Emiko Hori
Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan
3 shared publicationsHideaki Yahata
Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan
3 shared publicationsKaoru Okugawa
Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan
3 shared publications- Kazuo Asanoma
Department of Obstetrics and Gynecology, Kyushu University Hospital, Fukuoka, Japan
3 shared publications
Latest Publications
- Open Access
- 10 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (6) , 671
Low-Grade Endometrial Cancer with Abnormal p53 Expression as a Separate Clinical Entity: Insights from RNA Sequencing and Immunohistochemistry
Background: A molecular classification of endometrial cancer was developed based on an analysis of The Cancer Genome Atlas. In this classification, the group characterized by abnormal p53 immunohistochemical expression showed the poorest prognosis. However, there may be no need to apply a molecular classification in low-grade endometrial cancer. In this study, we investigated the clinical significance of abnormal p53 immunohistochemical expression in low-grade endometrial cancer. Methods: We obtained nine frozen samples of endometrial cancer [low-grade endometrial cancer with wild-type p53 expression (EClop53wt group): n = 3, low-grade endometrial cancer with abnormal p53 expression (EClop53ab group): n = 3, and high-grade endometrial cancer (EChi group): n = 3]. RNA sequencing was performed for each sample. All the samples passed RNA quality control. In addition, an immunohistochemical analysis was performed for 44 formalin-fixed paraffin-embedded samples. Results: Differentially expressed genes were identified in the RNA sequencing results (1811 genes between the EClop53ab group and the EChi group, and 1088 genes between the EClop53ab group and the EClop53wt group). In a principal component analysis, the EClop53ab group was more similar to the EClop53wt group than to the EChi group. In the immunohistochemical analysis, L1CAM expression was significantly less frequently observed in the EClop53ab group than in the EChi group. Moreover, p21 expression tended to be more frequently observed in the EClop53ab group than in the EChi group. Conclusions: In this study, the RNA sequencing and immunohistochemical results revealed that the EClop53ab group is a separate entity from the EChi group. While the abnormal p53 group is considered the most prognostically unfavorable in molecular classification, these findings suggest that routine molecular profiling is not necessary for patients with low-grade endometrial cancer. However, there is insufficient evidence to modify adjuvant treatment in low-grade endometrial cancer patients. Further investigation is needed on the clinical application of molecular classification to low-grade endometrial cancer.
- 10 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (6) , 671
Open AccessLow-Grade Endometrial Cancer with Abnormal p53 Expression as a Separate Clinical Entity: Insights from RNA Sequencing and Immunohistochemistry
Background: A molecular classification of endometrial cancer was developed based on an analysis of The Cancer Genome Atlas. In this classification, the group characterized by abnormal p53 immunohistochemical expression showed the poorest prognosis. However, there may be no need to apply a molecular classification in low-grade endometrial cancer. In this study, we investigated the clinical significance of abnormal p53 immunohistochemical expression in low-grade endometrial cancer. Methods: We obtained nine frozen samples of endometrial cancer [low-grade endometrial cancer with wild-type p53 expression (EClop53wt group): n = 3, low-grade endometrial cancer with abnormal p53 expression (EClop53ab group): n = 3, and high-grade endometrial cancer (EChi group): n = 3]. RNA sequencing was performed for each sample. All the samples passed RNA quality control. In addition, an immunohistochemical analysis was performed for 44 formalin-fixed paraffin-embedded samples. Results: Differentially expressed genes were identified in the RNA sequencing results (1811 genes between the EClop53ab group and the EChi group, and 1088 genes between the EClop53ab group and the EClop53wt group). In a principal component analysis, the EClop53ab group was more similar to the EClop53wt group than to the EChi group. In the immunohistochemical analysis, L1CAM expression was significantly less frequently observed in the EClop53ab group than in the EChi group. Moreover, p21 expression tended to be more frequently observed in the EClop53ab group than in the EChi group. Conclusions: In this study, the RNA sequencing and immunohistochemical results revealed that the EClop53ab group is a separate entity from the EChi group. While the abnormal p53 group is considered the most prognostically unfavorable in molecular classification, these findings suggest that routine molecular profiling is not necessary for patients with low-grade endometrial cancer. However, there is insufficient evidence to modify adjuvant treatment in low-grade endometrial cancer patients. Further investigation is needed on the clinical application of molecular classification to low-grade endometrial cancer.
- 5 June 2023
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 46 (9) , 387-391
Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval
Objective: The aim of this study was to evaluate the progression-free survival (PFS) and overall response rate (ORR) of patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) retreated with platinum-containing chemotherapy (PCC) based on the platinum-free interval (PFI). We compared our results with those reported in the KEYNOTE-775 study (that used pembrolizumab plus lenvatinib). Methods: A retrospective analysis was conducted of 65 patients with REC or AEC retreated with PCC between 2005 and 2020 at our hospital. Various clinicopathologic variables were analyzed: (1) age, (2) performance status, (3) histology, (4) history of pelvic irradiation in the adjuvant setting, (5) PFI, (6) chemotherapy regimen, (7) PFS and overall survival after retreatment with PCC, and (8) best ORR. Survival analyses were performed using Kaplan-Meier curves and log-rank tests. Results: The best ORR and PFS were 43.3% and 9.5 months, respectively, in patients with REC/AEC with a PFI ≥6 months. These results were comparable with those of patients treated with pembrolizumab and lenvatinib. The best ORR and PFS of patients with a PFI of <6 months appeared to be inferior to those of patients treated with pembrolizumab plus lenvatinib. Conclusions: Pembrolizumab plus lenvatinib seems to be a better treatment choice for patients with REC or AEC with a PFI of <6 months. For a PFI of ≥6 months, pembrolizumab plus lenvatinib or PCC can be used depending on the degree of residual side -effects associated with cytotoxic agents.
- 5 June 2023
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 46 (9) , 387-391
Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval
Objective: The aim of this study was to evaluate the progression-free survival (PFS) and overall response rate (ORR) of patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) retreated with platinum-containing chemotherapy (PCC) based on the platinum-free interval (PFI). We compared our results with those reported in the KEYNOTE-775 study (that used pembrolizumab plus lenvatinib). Methods: A retrospective analysis was conducted of 65 patients with REC or AEC retreated with PCC between 2005 and 2020 at our hospital. Various clinicopathologic variables were analyzed: (1) age, (2) performance status, (3) histology, (4) history of pelvic irradiation in the adjuvant setting, (5) PFI, (6) chemotherapy regimen, (7) PFS and overall survival after retreatment with PCC, and (8) best ORR. Survival analyses were performed using Kaplan-Meier curves and log-rank tests. Results: The best ORR and PFS were 43.3% and 9.5 months, respectively, in patients with REC/AEC with a PFI ≥6 months. These results were comparable with those of patients treated with pembrolizumab and lenvatinib. The best ORR and PFS of patients with a PFI of <6 months appeared to be inferior to those of patients treated with pembrolizumab plus lenvatinib. Conclusions: Pembrolizumab plus lenvatinib seems to be a better treatment choice for patients with REC or AEC with a PFI of <6 months. For a PFI of ≥6 months, pembrolizumab plus lenvatinib or PCC can be used depending on the degree of residual side -effects associated with cytotoxic agents.
- Open Access
Secondary Adrenal Insufficiency Due to Isolated ACTH Deficiency Induced by Pembrolizumab: A Report of Two Cases of Uterine Endometrial Cancer
Immune checkpoint inhibitors (ICIs) enhance antitumoral immune mechanisms and are used to treat various types of solid tumors including those that are microsatellite instability (MSI)-high. Uterine endometrial cancer is one of the most frequent tumor types that shows MSI-high, and, consequently, opportunities to use ICIs for endometrial cancer treatment are increasing. While using ICIs, it is important to monitor and manage various immune-related adverse events (irAEs). Here, we report two cases of secondary adrenal insufficiency during treatment of endometrial cancer with pembrolizumab. Both cases showed appetite loss and general fatigue after the 6th or 12th cycle of pembrolizumab. They were admitted to our hospital because of remarkable hyponatremia. Both cases showed no adrenocorticotropic hormone (ACTH) or cortisol response to CRH loading tests. Other pituitary hormone levels were normal, and MRI revealed no sign of hypophysitis in either patient. They were diagnosed with secondary adrenal insufficiency due to isolated ACTH deficiency and recovered soon after the administration of hydrocortisone and hydration. Thus, we should be aware of irAEs with the use of ICIs. In particular, adrenocortical insufficiency is sometimes lethal without appropriate treatment. Because the clinical symptoms are fatigue, appetite loss, and nausea, patients might be misjudged to have symptoms related to cancer. Checking serum morning cortisol before ICIs use and monitoring serum sodium levels could provide clues to diagnose secondary adrenal insufficiency.
Open AccessSecondary Adrenal Insufficiency Due to Isolated ACTH Deficiency Induced by Pembrolizumab: A Report of Two Cases of Uterine Endometrial Cancer
Immune checkpoint inhibitors (ICIs) enhance antitumoral immune mechanisms and are used to treat various types of solid tumors including those that are microsatellite instability (MSI)-high. Uterine endometrial cancer is one of the most frequent tumor types that shows MSI-high, and, consequently, opportunities to use ICIs for endometrial cancer treatment are increasing. While using ICIs, it is important to monitor and manage various immune-related adverse events (irAEs). Here, we report two cases of secondary adrenal insufficiency during treatment of endometrial cancer with pembrolizumab. Both cases showed appetite loss and general fatigue after the 6th or 12th cycle of pembrolizumab. They were admitted to our hospital because of remarkable hyponatremia. Both cases showed no adrenocorticotropic hormone (ACTH) or cortisol response to CRH loading tests. Other pituitary hormone levels were normal, and MRI revealed no sign of hypophysitis in either patient. They were diagnosed with secondary adrenal insufficiency due to isolated ACTH deficiency and recovered soon after the administration of hydrocortisone and hydration. Thus, we should be aware of irAEs with the use of ICIs. In particular, adrenocortical insufficiency is sometimes lethal without appropriate treatment. Because the clinical symptoms are fatigue, appetite loss, and nausea, patients might be misjudged to have symptoms related to cancer. Checking serum morning cortisol before ICIs use and monitoring serum sodium levels could provide clues to diagnose secondary adrenal insufficiency.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (3)
An update of oncologic and obstetric outcomes after abdominal trachelectomy using the FIGO 2018 staging system for cervical cancer: a single-institution retrospective analysis
Okugawa K, et al. J Gynecol Oncol. 2023 Jan;34:e41. https://doi.org/10.3802/jgo.2023.34.e41
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (3)
Open AccessAn update of oncologic and obstetric outcomes after abdominal trachelectomy using the FIGO 2018 staging system for cervical cancer: a single-institution retrospective analysis
Okugawa K, et al. J Gynecol Oncol. 2023 Jan;34:e41. https://doi.org/10.3802/jgo.2023.34.e41
- Open Access
- 13 December 2022
- Published by Qeios Ltd
Review of: "Challenges in identifying biomarkers for Smooth muscle tumors of uncertain malignant potential (STUMP)"
Thank you for inviting me to review for this manuscript. I’m agree with your opinion that it is necessary to predict a clinical course of uterine mesenchymal tumors by not only pathological findings but also key biomarkers that has been found by...
- 13 December 2022
- Published by Qeios Ltd
Open AccessReview of: "Challenges in identifying biomarkers for Smooth muscle tumors of uncertain malignant potential (STUMP)"
Thank you for inviting me to review for this manuscript. I’m agree with your opinion that it is necessary to predict a clinical course of uterine mesenchymal tumors by not only pathological findings but also key biomarkers that has been found by...
- Open Access
- 7 September 2022
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 61 (5) , 818-822
Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
- 7 September 2022
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 61 (5) , 818-822
Open AccessPrognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
- 11 November 2021
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 30 (4) , 427-431
A Case of Malignant Phyllodes Tumor of the Breast Metastasizing to the Ovary
Phyllodes tumors of the breast are uncommon, and 6.2% of phyllodes tumors behave in a malignant fashion. The metastatic spread of malignant phyllodes tumor is mainly hematogenous to lung and bone, and malignant phyllodes tumor metastasizing to the ovary is rare, with only 2 cases reported. We report the third case of metastatic malignant phyllodes tumor to the ovary with a focus on the differential diagnosis of ovarian cancer.
- 11 November 2021
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 30 (4) , 427-431
A Case of Malignant Phyllodes Tumor of the Breast Metastasizing to the Ovary
Phyllodes tumors of the breast are uncommon, and 6.2% of phyllodes tumors behave in a malignant fashion. The metastatic spread of malignant phyllodes tumor is mainly hematogenous to lung and bone, and malignant phyllodes tumor metastasizing to the ovary is rare, with only 2 cases reported. We report the third case of metastatic malignant phyllodes tumor to the ovary with a focus on the differential diagnosis of ovarian cancer.
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (4)
Safety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis
Okugawa K, et al. J Gynecol Oncol. 2019 Jun;31:e41. https://doi.org/10.3802/jgo.2020.31.e41
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (4)
Open AccessSafety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis
Okugawa K, et al. J Gynecol Oncol. 2019 Jun;31:e41. https://doi.org/10.3802/jgo.2020.31.e41
- 1 September 1995
- Published by Springer Nature in Journal of Hepato-Biliary-Pancreatic Surgery
- Vol. 2 (3) , 229-232
Hilar bile duct resection for bile duct carcinoma at the hilus of the liver
- 1 September 1995
- Published by Springer Nature in Journal of Hepato-Biliary-Pancreatic Surgery
- Vol. 2 (3) , 229-232
Hilar bile duct resection for bile duct carcinoma at the hilus of the liver
- Open Access
- 1 January 1992
- Published by Kurume Medical Journal in The Kurume Medical Journal
- Vol. 39 (4) , 231-234
Incidence of Hepatitis D Virus Infection in Japanese Patients with Hepatocellular Carcinoma Immunohistochemical Investigation of the Delta Antigen.
In order to clarify the incidence of the delta agent among hepatocellular carcinomas (HCCs) in Kurume, where the hepatitis B infection and its related HCC are most prevalent in Japan, liver tissues from sero hepatitis B surface antigen-positive autopsy cases, with or without HCC, were immunohistochemically investigated for detection of the delta antigen. Only one patient (1.7%) among 58 patients with HCC was found to have delta-antigen in the nuclei in the hepatocytes, which were diffusely distributed throughout the non-cancerous liver. None of 26 patients with liver cirrhosis showed delta-antigen in the liver tissue. The incidence is so low that the delta agent is unlikely to have a role in the development of HCC in our areas.
- 1 January 1992
- Published by Kurume Medical Journal in The Kurume Medical Journal
- Vol. 39 (4) , 231-234
Open AccessIncidence of Hepatitis D Virus Infection in Japanese Patients with Hepatocellular Carcinoma Immunohistochemical Investigation of the Delta Antigen.
In order to clarify the incidence of the delta agent among hepatocellular carcinomas (HCCs) in Kurume, where the hepatitis B infection and its related HCC are most prevalent in Japan, liver tissues from sero hepatitis B surface antigen-positive autopsy cases, with or without HCC, were immunohistochemically investigated for detection of the delta antigen. Only one patient (1.7%) among 58 patients with HCC was found to have delta-antigen in the nuclei in the hepatocytes, which were diffusely distributed throughout the non-cancerous liver. None of 26 patients with liver cirrhosis showed delta-antigen in the liver tissue. The incidence is so low that the delta agent is unlikely to have a role in the development of HCC in our areas.